Curis, Inc. — 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012; the filing was signed March 13, 2013. Although the request identifies 2012 Q4, this is an annual report covering the full year, with unaudited quarterly data also provided.
Business context
Curis is an oncology-focused drug developer with a largely clinical-stage pipeline. Its lead program, Erivedge (vismodegib), was approved in the U.S. in January 2012 for advanced basal cell carcinoma (BCC) and is commercialized by Genentech/Roche. Curis depends heavily on collaborators and licensees for development and commercialization; it has no product sales infrastructure of its own.
Financial performance and liquidity
| Metric | 2012 | 2011 |
|---|---|---|
| Revenue | $17.0 million | $14.8 million |
| Operating expenses | $35.6 million | $22.0 million |
| Loss from operations | $18.6 million | $7.2 million |
| Net loss | $16.4 million | $9.9 million |
| Net loss per share, basic and diluted | $0.21 | $0.13 |
| Cash, cash equivalents and investments at year-end | $58.7 million | $37.7 million |
| Working capital at year-end | $52.9 million | $34.7 million |
| Net cash used in operating activities | $15.2 million | $4.6 million |
2012 revenue comprised $14.0 million in license fees, $1.5 million in Erivedge royalties and $1.4 million in research and development revenue. Genentech-related milestones and royalties accounted for 94% of revenue; LLS accounted for 6%. A conventional product gross margin is not meaningful for this collaboration- and development-driven business.
Curis reported a $12.4 million net loss in Q4 2012, including $1.7 million revenue and a one-time $9.5 million in-process research and development charge for licensing CUDC-427. Q1 2012 reported net income of $2.2 million, largely reflecting milestone revenue; results therefore varied substantially by milestone timing and one-off items.
At December 31, 2012, Curis had $12.7 million in cash and cash equivalents, $42.8 million in short-term investments and $3.2 million in long-term investments. It also reported $30.2 million of debt including accrued interest (debt carrying value was $29.8 million, net of issuance costs). Current liabilities were $4.0 million; the debt was classified as long-term. The filing estimates operations can be funded into mid-2015 and projects year-end 2013 cash, cash equivalents, marketable securities and investments of $31 million to $36 million.
Material changes versus the prior year
- Revenue increased 15%, principally due to $1.5 million in newly recognized Erivedge royalties and $1.0 million in LLS milestones; license-fee revenue was slightly lower.
- Net loss widened to $16.4 million from $9.9 million. Operating costs rose sharply, including the $9.5 million CUDC-427 license and technology-transfer charge; R&D expense increased 13% and general and administrative expense increased 26%.
- Operating cash use increased to $15.2 million from $4.6 million, while financing cash flow included the new $30 million royalty-backed loan.
- Year-end cash, cash equivalents and investments rose by $21.0 million, supported in part by the loan and other financing proceeds; total liabilities increased to $35.5 million from $8.3 million.
Outlook, management commentary and risks
- Management expected 2013 R&D expense of $16 million to $20 million and general and administrative expense of $10 million to $12 million. It expected higher development spending as clinical trials advance.
- Curis licensed CUDC-427 from Genentech in November 2012 for an upfront and technology-transfer cost of $9.5 million; Curis planned additional clinical development in 2013. CUDC-907 entered Phase I in January 2013, with up to $4 million in LLS milestone support. CUDC-101’s oral formulation study was stopped after inadequate drug exposure; its intravenous program continued in Phase I.
- Erivedge was under regulatory review in Europe, Australia and other territories. Management cited potential European approval in the first half of 2013 and anticipated additional regulatory milestones if approvals were obtained. These were expectations, not guaranteed outcomes.
- The $30 million BioPharma-II loan bears 12.25% annual interest and is secured by specified Erivedge royalty and royalty-related payments. After specified deductions, payments toward the loan are capped at $1 million per quarter in 2013, $2 million in 2014 and $3 million in 2015; unpaid interest may be added to principal. Curis estimated repayment by early 2017, dependent on royalty levels. Most or all near-term royalties may service the debt, restricting cash available to Curis.
- Curis had an accumulated deficit of $748.5 million and expected continuing losses; profitability was not expected in the foreseeable future. It may need additional financing or collaborations, which may be unavailable on acceptable terms, dilute shareholders or require relinquishing rights.
- Principal risks include dependence on Genentech/Roche for Erivedge commercialization and regulatory progress, early-stage clinical uncertainty, reliance on third parties, intense competition, patent and manufacturing risks, and the potential need for further capital. Erivedge royalty receipts are concentrated and encumbered by the loan.
- Management and the independent auditor reported effective internal control over financial reporting. The auditor issued an unqualified opinion on the financial statements and internal controls. Curis reported no material legal proceedings.
Most important facts for investors to verify
- Erivedge’s sales, royalty trajectory and regulatory progress outside the U.S., and how royalty receipts are allocated between the debt and Curis.
- The actual loan balance, interest accrual, repayment pace, covenants and any changes to the estimated early-2017 payoff.
- Cash burn against the mid-2015 runway estimate, including actual 2013 spending and whether new financing or partnering is needed.
- Clinical safety, efficacy, enrollment and funding milestones for CUDC-427, CUDC-907 and CUDC-101; the filing’s post-year-end trial updates should not be treated as 2012 results.
- Revenue concentration and the timing and probability of contingent milestone payments; 2012 revenue does not establish recurring or profitable operations.
- Potential dilution from stock options, warrants and equity issuance. The filing reported 10.4 million options and 1.4 million warrants outstanding at year-end.